⌕
Kailera Therapeutics · KLRA · Nasdaq
Tenet — · insufficient data
Compare
$12.57−5.28%At close
$12.57−0.70 (−5.28%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Kailera Therapeutics (KLRA) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is KLRA's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● GlobeNewsWireNov 10, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Kailera Therapeutics to Present at ObesityWeek 2026

Ribupatide injection Phase 3 KaiNETIC trial design presentations highlight its potential to address diverse needs across the obesity spectrum Real-world obesity management presentation highlights the clinical unmet needs…

KLRA −5.3% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates

Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA Ribupatide injection Phase 2b trial and KaiNETIC global Phase 3 program fully enrolled; data exp…

KLRA −5.3% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 07:15 ETCOMPANY'S OWN WORDS
Kailera Therapeutics to Participate in November Investor Conferences

Ron Renaud, President and Chief Executive Officer, and additional members of the management team will participate in the following investor conferences…

KLRA −5.3% todayRead at source ↗
● Defense WorldOct 11, 2026 · 03:01 ET
Kailera Therapeutics (NASDAQ:KLRA) Shares Climb 7.6% – Here’s What Happened

Kailera Therapeutics, Inc. (NASDAQ: KLRA - Get Free Report)'s stock price was up 7.6% on Friday. The stock traded as high as $10.76 and last traded at $10.76. 293,082 shares were traded during mid-day trading, a decline …

KLRA −5.3% todayRead at source ↗
● Defense WorldOct 5, 2026 · 11:02 ET
Kailera Therapeutics (NASDAQ:KLRA) Sets New 12-Month Low – Time to Sell?

Kailera Therapeutics, Inc. (NASDAQ: KLRA - Get Free Report)'s share price reached a new 52-week low on Monday. The stock traded as low as $10.20 and last traded at $10.20, with a volume of 51759 shares. The stock had pre…

KLRA −5.3% todayRead at source ↗
● GlobeNewsWireOct 1, 2026 · 06:45 ETCOMPANY'S OWN WORDS
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting

- New Phase 1 data highlight flexibility of injection site for ribupatide injection - Four additional oral presentations from Hengrui Pharma add to the clinical evidence behind Kailera's pipeline WALTHAM, Mass., Oct. 01,…

KLRA −5.3% todayRead at source ↗
● GlobeNewsWireSep 30, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection

- Ribupatide injection (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m² or higher - Topline data now expected in mid-2028 WALTHAM, Mass., Sept. 30, 202…

KLRA −5.3% todayRead at source ↗
● Seeking AlphaSep 17, 2026 · 11:42 ET
Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval

Kailera Therapeutics, Inc. targets the high-potential GLP-1 obesity market, leveraging a $718M IPO and a robust pipeline licensed from Hengrui. KLRA's lead candidate, ribupatide, shows competitive mean weight loss (23.6%…

KLRA −5.3% todayRead at source ↗
● GlobeNewsWireSep 16, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Kailera Therapeutics to Participate in September Investor Conferences

WALTHAM, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced participat…

KLRA −5.3% todayRead at source ↗
● Defense WorldSep 4, 2026 · 03:24 ET
Atlas Venture Life Science Advisors LLC Makes New Investment in Kailera Therapeutics, Inc. $KLRA

Atlas Venture Life Science Advisors LLC acquired a new position in shares of Kailera Therapeutics, Inc. (NASDAQ: KLRA) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commi…

KLRA −5.3% todayRead at source ↗
● 24/7 Wall StreetAug 18, 2026 · 10:10 ET
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore

Kailera Therapeutics (NASDAQ:KLRA) closed most recently at $18.51, between a post-IPO high of $28.23 and low of $16.39, with a $2.40 billion market cap.…

KLRA −5.3% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just KLRA · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.